TCGA-43-A475-01A-11R-A24H-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.480
- INTERFERON_GAMMA_RESPONSE+0.410
- E2F_TARGETS+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- INTERFERON_ALPHA_RESPONSE+0.340
- G2M_CHECKPOINT+0.330
- MYC_TARGETS_V2+0.300
- IL6_JAK_STAT3_SIGNALING+0.290
- APICAL_SURFACE+0.270
- INFLAMMATORY_RESPONSE+0.190
Top 10 suppressed
- ANGIOGENESIS-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- TGF_BETA_SIGNALING-0.360
- COAGULATION-0.340
- HYPOXIA-0.340
- MYOGENESIS-0.320
- GLYCOLYSIS-0.290
- ADIPOGENESIS-0.250
- ESTROGEN_RESPONSE_EARLY-0.250
- NOTCH_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613734 | — | D | 0.857 |
| 2 | SRR8518222 | — | D | 0.848 |
| 3 | MBCProject_5971_T1_RNA | — | D | 0.838 |
| 4 | becdc4f8-3eee-4085-9046-31c7a059adff | — | — | 0.830 |
| 5 | SRR8613746 | — | D | 0.825 |
| 6 | MBCProject_1542_T2_RNA | — | D | 0.825 |
| 7 | SRR25617828 | — | D | 0.821 |
| 8 | TCGA-GM-A2DH-01A-11R-A180-07 | — | C | 0.816 |
| 9 | BSR_11_0107_E3_S77 | — | D | 0.813 |
| 10 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |